c-myb hyperactivity leads to myeloid and lymphoid malignancies in zebrafish.

c-myb hyperactivity leads to myeloid and lymphoid malignancies in zebrafish.
复制标题

c-myb 过度活跃会导致斑马鱼出现骨髓和淋巴恶性肿瘤。

DOI:
10.1038/leu.2016.170
复制
发表时间:
2017-01
期刊:
影响因子:
11.4
通讯作者:
Zhang W
Zhang W
中科院分区:
医学1区
文献类型:
--
作者:
Liu W;Wu M;Huang Z;Lian J;Chen J;Wang T;Leung AY;Liao Y;Zhang Z;Liu Q;Yen K;Lin S;Zon LI;Wen Z;Zhang Y;Zhang W

文献摘要

参考文献

被引文献

相似文献

c-MYB转录因子是造血细胞增殖和分化的关键调节因子,c-MYB活性失调通常与各种血液疾病相关。然而,由于缺乏合适的动物模型,其致病作用仍然很大程度上未知。在这里,我们报告了具有 c-Myb 过度活性(称为 c-mybhyper)的 c-myb-gfp 转基因斑马鱼的详细特征。该细胞系从胚胎期到成年期表现出异常的粒细胞扩张,类似于人类骨髓增生异常综合征(MDS)。引人注目的是,随着年龄的增长,一小部分 c-mybhyper 成鱼会出现急性髓细胞白血病样或急性淋巴白血病样疾病。 c-mybhyper成鱼的骨髓和淋巴恶性肿瘤可能是由c-myb过度活跃引起的,导致许多细胞周期相关基因失调和造血前体细胞过度增殖。最后,用c-myb靶向药物flavopiridol治疗可以缓解c-mybhyper胚胎和成鱼的MDS样症状。我们的研究建立了斑马鱼模型,用于研究 c-Myb 相关白血病发生的细胞和分子机制以及抗白血病药物筛选。
The c-MYB transcription factor is a key regulator of hematopoietic cell proliferation and differentiation, and dysregulation of c-MYB activity often associates with various hematological disorders. Yet, its pathogenic role remains largely unknown due to lack of suitable animal models. Here, we report a detail characterization of a c-myb-gfp transgenic zebrafish harboring c-Myb hyperactivity (named c-mybhyper). This line exhibits abnormal granulocyte expansion that resembles human myelodysplastic syndrome (MDS) from embryonic stage to adulthood. Strikingly, a small portion of c-mybhyper adult fish develops acute myeloid leukemia-like or acute lymphoid leukemia-like disorders with age. The myeloid and lymphoid malignancies in c-mybhyper adult fish are likely caused by the hyperactivity of c-myb, resulting in the dysregulation of a number of cell-cycle-related genes and hyperproliferation of hematopoietic precursor cells. Finally, treatment with c-myb target drug flavopiridol can relieve the MDS-like symptoms in both c-mybhyper embryos and adult fish. Our study establishes a zebrafish model for studying the cellular and molecular mechanisms underlying c-Myb-associated leukemogenesis as well as for anti-leukemic drug screening.
DOI: 10.1016/j.leukres.2009.11.007
发表时间: 2010-07
期刊: Leukemia research
影响因子: 2.7
作者:
Karp JE;Blackford A;Smith BD;Alino K;Seung AH;Bolaños-Meade J;Greer JM;Carraway HE;Gore SD;Jones RJ;Levis MJ;McDevitt MA;Doyle LA;Wright JJ
通讯作者: Wright JJ
DOI: 10.1016/0145-2126(92)90080-q
发表时间: 1992-10-01
期刊: LEUKEMIA RESEARCH
影响因子: 2.7
作者:
GOPAL, V;HULETTE, B;PREISLER, H
通讯作者: PREISLER, H
DOI: 10.1038/leu.2008.257
发表时间: 2009-01-01
期刊: LEUKEMIA
影响因子: 11.4
作者:
Murati, A.;Gervais, C.;Birnbaum, D.
通讯作者: Birnbaum, D.
DOI: 10.1002/aja.1002030302
发表时间: 1995-07-01
影响因子: 2.5
作者:
KIMMEL, CB;BALLARD, WW;SCHILLING, TF
通讯作者: SCHILLING, TF
DOI: 10.1016/s0925-4773(01)00658-x
发表时间: 2002-04-01
影响因子: 2.6
作者:
Liu, F;Wen, ZL
通讯作者: Wen, ZL